In October 2010, Gene Frontier took a new step as a member of the Kaneka Group. Former Gene Frontier, the predecessor, has been striving as a leading domestic company in the microarray business and antibody-related business since its establishment in 2003. Since 2008, the company has focused on protein and antibody-related businesses. In antibody-related businesses, we have been developing business in close collaboration with our partner partner MorphoSys. In recent years, antibody drugs have been able to specifically attack proteins that become disease-related factors by utilizing the inherent property of antibodies that bind only to target cells such as cancer cells, and have a breakthrough with fewer side effects. Because of the therapeutic effects, development competition is occurring worldwide. We use fully artificial recombinant human antibody production technology introduced from Germany's MorphoSys to promote antibody drug target search business through joint research with other companies and other organizations, and licensing to Japanese bio-drug discovery companies. We are actively working to further accelerate biopharmaceutical research and development. Gene Frontier has expanded its business domains that lead to the acceleration of biopharmaceuticals including antibody drugs, and is also developing its own technologies. In the future, with the support of Kaneka, we will accelerate research and development and business development, and aim for further growth toward the world. Gene Frontier shares Kaneka's corporate vision, “To be more surprised, to Mirai.” And will continue to provide unique technologies and services for the development of innovative medicines and diagnostics. As a partner, we will contribute to medical treatment in the 21st century.

Eisai R&D Management Co., Ltd., a subsidiary of Eisai Co., Ltd., is a company headquartered in Bunkyo, Japan. The firm engages in research and development of pharmaceuticals.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Todos Medical Ltd. is an in vitro diagnostics company. It is focused on the development of novel blood tests for the early detection of cancer and Alzheimer's disease, and the distribution of comprehensive solutions for COVID-19 screening. It is also involved in the activities of breast cancer test, such as TM-B1 and TM-B2. The company was founded by Rami Zigdon and Udi Zelig on April 22, 2010 and is headquartered in Tel Aviv, Israel.

Celularity, Inc. a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert J. Hariri in 2016 and is headquartered in Florham Park, NJ.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

InDex Pharmaceuticals AB is a pharmaceutical development company, which engages in the research, development of technology, and commercialization of scientific discoveries focusing on immunological diseases. It also offers the drug candidate cobitolimod and DiBiCol diagnostic kit. The company was founded was founded on December 14, 2015 and is headquartered in Solna, Sweden.

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the \"ARCHER\" trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

Lophius Biosciences is a young biotechnology company developing innovative products for the diagnosis of acute infectious and autoimmune diseases. The company is also offering custom-made services in the area of cell based bioactivity and quality tests for pharmaceutical agents. The core competencies of Lophius Biosciences are in the area of Immunology and T-cell diagnostics. Lophius Biosciences is a privately-held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases. The company’s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation® and Reverse T Cell Technology platforms. Whereas the T-activation® technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics.

Immunex Corporation develops, manufactures, and markets therapeutic products for the treatment of cancer, infectious diseases, and autoimmune disorders. It offers products, such as Enbrel that is used in the treatment of rheumatoid arthritis; Novantrone, which is used to treat acute nonlymphocytic leukemia and pain associated with prostate cancer; and Leukine for use in bone marrow transplant patients. The company has franchise operations. It has a strategic alliance with American Home Products. The company was founded in 1981 and is based in Seattle, Washington. As of July 15, 2002, Immunex Corporation was acquired by Amgen, Inc.

Develops pharmaceuticals

UK Research & Innovation (doing business as United Kingdom Research & Innovation) is a private company headquartered in London, UK. The firm provides science and technology research services.\nThe company says this about itself: Innovate UK is part of UK Research and Innovation, a non-departmental public body funded by a grant-in-aid from the UK government. We drive productivity and economic growth by supporting businesses to develop and realise the potential of new ideas, including those from the UK’s world-class research base.

Beijing Histe Medical Laboratory Co., Ltd., established on 2005-08-26, The scope of business includes medical laboratory;clinical body fluid,blood specialty;clinical chemistry laboratory;clinical immunization,Serology major;Clinical Cytomolecular Genetics Major/Pathology(The medical institution practice license is valid until2025year06moon01day);technology development,technology transfer,technical consulting,Technical Services;Sales of chemical products(Does not contain dangerous chemicals and a class of precursor drugs),Instrumentation,Equipment(Cars not included),Class I medical device;Import and export,Technology Import and Export,Agent import and export.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Medical Laboratory;clinical body fluid,blood specialty;clinical chemistry laboratory;clinical immunization,Serology major;Clinical Cytomolecular Genetics Major/Department of Pathology and programs subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.